Abstract A 54-year-old woman presented with hematopyuria. She had experienced difficulty in urinating since undergoing surgery for rectal cancer 15 years earlier.
Introduction
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) was first described by Isaacson and Wright [1] in 1983. In the World Health Organization's classification of neoplastic diseases of hematopoietic and lymphoid tissues, MALT lymphoma is defined as an extranodal lymphoma composed of morphologically heterogeneous small B cells including marginal zone (centrocyte-like) cells, monocytoid-like cells, small lymphocytes, and scattered immunoblast and centroblast-like cells [2] . The stomach is the most common site of involvement. MALT lymphoma has also been described in the lung, thyroid, salivary gland, orbit, conjunctiva, and various mucosal sites.
This report describes a case of MALT lymphoma in the urinary bladder of a 54-year-old woman who had chronic inflammation due to neurogenic bladder.
Case report
A 54-year-old woman with hematopyuria and bladder discomfort was referred to our hospital in March 2010. She had undergone surgery for rectal cancer 15 years earlier, and since then she had experienced difficulty in urinating. Although she had visited a local clinic and undergone antibiotic therapy 6 months earlier, the symptoms did not disappear.
Both white blood cells and red blood cells were detected in the urine ([100/HPF). Urine culture showed no significant bacterial growth. Cystoscopy showed a flat, sessile, elevated lesion, and urine cytology was negative. Contrastenhanced computed tomography (CT) revealed irregular thickening of the bladder wall and tumor-like masses (Fig. 1) .
Initially, because we diagnosed her as having chronic inflammation due to neurogenic bladder, we recommended that she perform clean intermittent self-catheterization to manage the neurogenic bladder. However, CT showed wall thickening progression and right hydronephrosis 3 months after the initial workup (Fig. 2) . We therefore performed a transurethral bladder tumor biopsy. Histopathological examination revealed diffuse infiltration of atypical lymphocytes (Fig. 3a) , and focal lymphoepithelial lesions (LEL) were also observed (Fig. 3b) . Atypical cells were small to medium in size with oval or round nuclei and abundant pale-staining cytoplasms, and resembled monocytoid cells. There was plasma cell differentiation (Fig. 3c) . In almost all fragments obtained by transurethral biopsy, the normal tissue cells had been replaced with lymphoma cells. Immunophenotyping revealed CD20? (Fig. 4a ), CD3- (Fig. 4b ), CD10- (Fig. 4c ), CD79a?, bcl-2?, CD5-, cyclin D1-and bcl-6-cells. On the basis of these observations, we diagnosed the bladder tumor as non-Hodgkin's lymphoma of the MALT type.
The results of a CT scan, gallium scintigraphy, positron emission tomography, and bone marrow biopsy suggested that it was a primary MALT lymphoma of the bladder, stage IE (Ann Arbor classification). Although curative radiotherapy was recommended, we were greatly concerned that it might lead to worsening of her bladder function. Urodynamic studies showed acontractile detrusor with low compliance.
Gastric MALT lymphoma is well known to be a slowgrowing disease and related to H. pylori infection. There have been reports of extragastric MALT lymphomas responding to anti-H. pylori-type antibiotic combinations or antibiotic therapy for urinary tract infection (UTI). Thus, we first treated her with antibiotics, including a cephem antibiotic. We also treated her to eradicate H. pylori, although the urea breath test was negative for H. pylori. One month later she underwent transurethral bladder tumor biopsy, which showed residual disease. Therefore, definitive radiation therapy (30 Gy) was administered to the bladder. Subsequent CT revealed disappearance of the wall thickening (Fig. 5) , and transurethral resection showed no residual lesion of malignant lymphoma. She has maintained a complete response (CR) for 9 months of follow-up at the time of writing. Follow-up urodynamic studies for evaluation of bladder function are scheduled.
Discussion
The earliest recorded case of primary lymphoma of the urinary bladder dates back to 1885, with just over 100 cases now reported [3] . The median age of patients at diagnosis is 69 (range 20-87) years. There is a notable female predominance of 2.7:1. Hematuria is the most common presenting symptom, followed by dysuria.
MALT lymphoma is a low-grade extranodal lymphoma whose histogenesis is from MALT [1] . The stomach is the most common and best-studied mucosal site of involvement [4] . However, this disease has also been described in various non-gastrointestinal sites, such as the lung, thyroid, salivary gland, conjunctiva, and orbit [5] . Kempton et al. [4] described that MALT lymphoma is the most frequently observed type of primary bladder lymphoma. To our knowledge, 20 cases of MALT lymphoma of the urinary bladder have been reported in Japan [6] [7] [8] [9] [10] [11] . Among them, the median age at diagnosis was 69 (range 27-85) years, and there was a female predominance of 9:1. Many cases of MALT lymphoma have a history of chronic inflammation. H. pylori infection is well known as a cause of gastric MALT lymphoma [5] . Development of MALT lymphoma has also been reported to be associated with autoimmune diseases such as Sjögren's syndrome or Hashimoto's disease. Chromosomal abnormalities are another reported cause [12] .
Chronic or recurrent UTI is a significant problem in all patients with neurogenic bladder. Patients with persistent bacteriuria or recurrent UTI have been shown to have significant B cell infiltration into the submucosa, including the lymphoid nodules. These inflammatory changes are likely due to antigenic stimulation from repeated exposure to bacteria [13] . Bacterial colonization of the gastric mucosa with H. pylori is known to trigger lymphoid infiltration and the formation of acquired MALT [14] . In our case, cystitis induced by repeated or prolonged UTI with neurogenic bladder might have been associated with the onset of the MALT lymphoma. To the best of our knowledge this is the first report of MALT lymphoma with neurogenic bladder dysfunction.
Patients with localized MALT lymphomas are usually referred for radiation, or sometimes for surgery, chemotherapy, immunotherapy, or a combination of those treatments. Goda et al. [15] reported the long-term outcome of localized MALT lymphomas treated with radiotherapy: the CR rate was 99 %, the 10-year recurrence-free rate was 76 %, and the overall survival rate was 87 %. These findings suggest that radiotherapy is a good choice in the interest of organ preservation, while also producing the desired therapeutic effect. Almost all patients who undergo radiotherapy receive 25-35 Gy of radiation as curative therapy. In the Japanese series, 13 of 20 patients had radiotherapy as treatment. Seven patients received chemotherapy such as CHOP or THPCOP, and three patients had rituximab alone or in combination with CHOP chemotherapy [6] [7] [8] [9] [10] [11] .
Eradication of H. pylori is established as an effective initial treatment for stage I gastric MALT lymphoma, and successful eradication leads to CR of the lymphoma in 80 % of cases [16] . Some cases of extragastric MALT lymphoma have also been treated by eradication of H. pylori. Fujimura et al. [9] reported that the lymphoma disappeared in a case of MALT lymphoma of the bladder with UTI that was treated with antibiotics for 2 weeks and with H. pylori eradication therapy. Bosch et al. [17] also reported the disappearance of a MALT lymphoma of the bladder after H. pylori eradication monotherapy.
On the other hand, Grünberger et al. [18] reported that H. pylori eradication was ineffective for the treatment of extragastric MALT lymphomas. They suggested that H. pylori does not play a role in the development of these lymphomas. The positive rate of H. pylori is more than 90 % in gastric MALT lymphomas, but only 45 % in extragastric MALT lymphomas. In our case, residual tumor tissue was observed in the pathological specimen after antibiotic therapy, but subsequent radiation therapy achieved CR. It is clear that this patient will require longterm follow-up of bladder function to evaluate the radiation-related adverse events.
In conclusion, MALT lymphomas can have a favorable prognosis, and patients can receive safe treatment with preservation of their quality of life. We hope to determine the cause of this disease from a molecular biological approach.
